Metformin may lower mortality in patients with diabetes and heart failure
Metformin, either alone or in combination with sulfonylurea, appears to increase 1-year and long-term survival in patients with type 2 diabetes mellitus and chronic heart failure, according to research published in the October 1 issue of the American Journal of Cardiology, HealthDay News reported.
Metformin, either alone or in combination with sulfonylurea, appears to increase 1-year and long-term survival in patients with type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF), according to research published in the October 1 issue of the American Journal of Cardiology, HealthDay News reported.
Josie M.M. Evans, PhD, of the University of Stirling, Scotland, UK, and colleagues used a prescription database and diabetes research data to identify 422 subjects with T2DM and incident CHF who were receiving oral hypoglycemic agents, but not insulin, to study the effect of metformin.
“Patients with T2DM and CHF who were treated with metformin alone or in combination with sulfonylureas were at significantly lower risk of all-cause mortality during 1-year and long-term follow-up than those who were treated with sulfonylurea alone,” Dr Evans told Formulary. “A clinical trial of patients with chronic heart failure receiving metformin is needed to corroborate these observational findings.”
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
